VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Obtained informed consent                          │ Obtained informed consent                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stable pharmacological therapy during the last 4   │ Stable pharmacological therapy during the last 4   │     100 │
│ weeks (with the exception of diuretics)            │ weeks (with the exception of diuretics)            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to Ferinject®               │ Known hypersensitivity to Ferinject®               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic liver disease and/or screening alanine     │ Chronic liver disease and/or screening alanine     │     100 │
│ transaminase (ALT) or aspartate transaminase (AST) │ transaminase (ALT) or aspartate transaminase (AST) │         │
│ above three times the upper limit of the normal    │ above three times the upper limit of the normal    │         │
│ range                                              │ range                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Immunosuppressive therapy or renal dialysis        │ Immunosuppressive therapy or renal dialysis        │     100 │
│ (current or planned within the next 6 months)      │ (current or planned within the next 6 months)      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of erythropoietin, i. v. or oral iron      │ History of erythropoietin, i. v. or oral iron      │     100 │
│ therapy, and blood transfusion in previous 12      │ therapy, and blood transfusion in previous 12      │         │
│ weeks and/or such therapy planned within the next  │ weeks and/or such therapy planned within the next  │         │
│ 6 months                                           │ 6 months                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unstable angina pectoris as judged by the          │ Unstable angina pectoris as judged by the          │     100 │
│ investigator, clinically significant uncorrected   │ investigator, clinically significant uncorrected   │         │
│ valvular disease or left ventricular outflow       │ valvular disease or left ventricular outflow       │         │
│ obstruction, obstructive cardiomyopathy, poorly    │ obstruction, obstructive cardiomyopathy, poorly    │         │
│ controlled fast atrial fibrillation or flutter,    │ controlled fast atrial fibrillation or flutter,    │         │
│ poorly controlled symptomatic brady- or            │ poorly controlled symptomatic brady- or            │         │
│ tachyarrhythmias                                   │ tachyarrhythmias                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute myocardial infarction or acute coronary      │ Acute myocardial infarction or acute coronary      │     100 │
│ syndrome, transient ischemic attack or stroke      │ syndrome, transient ischemic attack or stroke      │         │
│ within the last 3 months                           │ within the last 3 months                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Coronary-artery bypass graft, percutaneous         │ Coronary-artery bypass graft, percutaneous         │     100 │
│ intervention (e.g. cardiac, cerebrovascular,       │ intervention (e.g. cardiac, cerebrovascular,       │         │
│ aortic; diagnostic catheters are allowed) or major │ aortic; diagnostic catheters are allowed) or major │         │
│ surgery, including thoracic and cardiac surgery,   │ surgery, including thoracic and cardiac surgery,   │         │
│ within the last 3 months                           │ within the last 3 months                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in a CHF training program            │ Participation in a CHF training program            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known HIV/AIDS                                     │ Known HIV/AIDS                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to fully comprehend and/or perform study │ Inability to fully comprehend and/or perform study │     100 │
│ procedures in the investigator's opinion           │ procedures in the investigator's opinion           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Vitamin B12 and/or serum folate deficiency         │ Vitamin B12 and/or serum folate deficiency         │     100 │
│ according to the laboratory (re-screening is       │ according to the laboratory (re-screening is       │         │
│ possible after substitution therapy)               │ possible after substitution therapy)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or lactation                             │ Pregnancy or lactation                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial within     │ Participation in another clinical trial within     │     100 │
│ previous 30 days and/or anticipated participation  │ previous 30 days and/or anticipated participation  │         │
│ in another trial during this study                 │ in another trial during this study                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticoagulation                                    │ Anticoagulation                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥18 years                                      │ Age =18 years                                      │      92 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with chronic heart failure of New York    │ Patients with chronic heart failure of New York    │      99 │
│ Heart Association Class II or III, a left          │ Heart Association Class II or III, a left          │         │
│ ventricular ejection fraction of ≤ 40% for         │ ventricular ejection fraction of = 40% for         │         │
│ patients in NYHA class II or ≤ 45% for patients in │ patients in NYHA class II or = 45% for patients in │         │
│ NYHA class III, a hemoglobin level at the          │ NYHA class III, a hemoglobin level at the          │         │
│ screening visit between 9.5-13.5 g/dl, and iron    │ screening visit between 9.5-13.5 g/dl, and iron    │         │
│ deficiency, which is defined as serum ferritin     │ deficiency, which is defined as serum ferritin     │         │
│ level \< 100µg/l or between 100 and 299 µg/l, when │ level < 100µg/l or between 100 and 299 µg/l, when  │         │
│ transferring saturation is \< 20%                  │ transferring saturation is < 20%                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemochromatosis, iron overload, defined as TSAT \> │ Hemochromatosis, iron overload, defined as TSAT >  │      99 │
│ 45%                                                │ 45%                                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known active infection, CRP\>20 mg/L, clinically   │ Known active infection, CRP>20 mg/L, clinically    │      99 │
│ significant bleeding, active malignancy            │ significant bleeding, active malignancy            │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age =18 years   │      43 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.76190476190476
OverAll Ratio: 97.88095238095238
